Life sciences lawyers shocked and concerned amid Brexit uncertainty
17-01-2019
UK publishes further no-deal Brexit guidance for medicines
08-01-2019
Brexit draft deal: a welcome step but more certainty needed, say lawyers
16-11-2018
natasaadzic / iStockphoto.com
Associations representing the pharmaceutical and biotechnology fields have said that the UK should maintain “close cooperation” with the EU post-Brexit, to ensure that access to safe and effective medicines continues in both markets.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Association of the British Pharmaceutical Industry, BioIndustry Association, Brexit, Medicines and Healthcare Products Regulatory Agency, innovation
